- Voigt LF, Weiss NS. Epidemiology of endometrial cancer. Cancer Treat Res. 1989;49:1-21.
- Rose PG. Endometrial carcinoma. N Engl J Med. 1996;335:640-49.
- de Jonge MM, Mooyaart AL, Vreeswijk MP, et al. Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: a meta-analysis and case report. Eur J Cancer. 2017;72:215-25.
- Hafezi S, Nofech-Mozes S, Ismiil N, et al. Endometrioid endometrial adenocarcinoma (EEA) in elderly women: a clinic-pathologic study. Lab Invest. 2009;89: 216A.
- Brustein S, Fruchter R, Greene GL, Pertschuk LP. Immunocytochemical assay of progesterone receptors in paraffin-embedded specimens of endometrial carcinoma and hyperplasia. A preliminary evaluation. Mod Pathol. 1989;2:449-55.
- Hye- Rim Lee , Tae-Hee Kim,functions and physiological roles of two types of estrogen receptors , ER-a and ERB; 2012.
- scoring and reporting of estrogen receptor (ER) and progesterone receptor (PR) testing.Lab CE ; presented by media lab.
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
- Dossus, N. Allen, R. Kaaks et al., “Reproductive risk factors and endometrial cancer: the european prospective investigation into cancer and nutrition,” International Journal of Cancer, 2010;127: 442–51.
- -H. Xu, Y.-B. Xiang, Z.-X. Ruan et al., “Menstrual and reproductive factors and endometrial cancer risk: results from a population-based case-control study in urban shanghai,” International Journal of Cancer, 2004;108: 613–19.
- Trentham-Dietz, H. B. Nichols, J. M. Hampton, and P. A. Newcomb, “Weight change
and risk of endometrial cancer,” International Journal of Epidemiology, 2006;35:151–58.
- J. Wernli, R. M. Ray, D. L. Gao, A. J. De Roos, H. Checkoway, and D. B. Thomas,
“Menstrual and reproductive factors in relation to risk of endometrial cancer in Chinese women,” Cancer Causes & Control, 2006;17: 949–55.
- W. Setiawan, M. C. Pike, L. N. Kolonel, A. M. Nomura, M. T. Goodman, and B. E.
Henderson, “Racial/ethnic differences in endometrial cancer risk: the multiethnic cohort study,” American Journal of Epidemiology, 2007;165: 262–70.
- Zucchetto, D. Serraino, J. Polesel et al., “Hormone-related factors and gynecological
conditions in relation to endometrial cancer risk,” European Journal of Cancer Prevention, 2009;18:316–21.
- Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical
pathologic spread patterns of endometrial cancer. A gynecologic oncology group Cancer. 1987;60:2035–41.
- Abeler VM, Kjorstad KE. Endometrial adenocarcinoma in Norway: a study of a total
Cancer. 1991;67:3093–103.
- Eur J Gynaecol Oncol. Using FIGO histologic grade to determine when to perform
lymphadenectomies in endometrioid adenocarcinoma of the endometrium. 1996;17:204-7.
- KHUSHBAKHAT R. MITTAL, Architectural (FIGO) Grading, Nuclear Grading, and Other
Prognostic Indicators in Stage I Endometrial Adenocarcinoma With Identification of High-Risk and Low-Risk Groups. 1988;61:538-45.
- J Turk Ger Gynecol Assoc. comparison of preoperative endometrial biopsy grade and final
pathologic diagnosis in patients with endometrioid endometrial cancer. 2012; 13: 106–10.
- Querleu D, Planchamp F, Narducci F, Morice P, Joly F, Genestie C, Haie-Meder C, Thomas L, Quénel-Tueux N, Daraï E, Dorangeon PH, Marret H, Taïeb S, Mazeau-Woynar V; Institut National duCancer; Societe Francaise d’Oncologie Gynecologique: Clinical practice guidelines for the management of patients with endometrial cancer in France: recommendations of the Institut National du Cancer and the Societe Francaise d’Oncologie Gynecologique. Int J Gynecol Cancer 2011;21: 945- 50.
- Ballester M, Naoura I, Chereau E, Seror J, Bats AS, Bricou A and Daraï E: Sentinel node biopsy upstages patients with presumed low- and intermediate-risk endometrial cancer: results of a multicenter study. Ann Surg Oncol 2012;20: 407-12.
- ANDREW BERCHUCK , M.D.Pastsurgical surveillance of patients with stage I\II endometrial adenocarcinoma . 1995;59:20-24.
- A. Elshaikh, R. Cattaneo II, G. Jacobsen, and R. Hanna; Henry Ford Health System, Detroit, MI. Interval Between Hysterectomy and Start of Radiation Treatment is Predictive of Recurrence in Patients With Endometrial Carcinoma – A Single Institution Experience . 2012; 84 : 3S Supplement.
- F. Dunn, V. Gondi, K.A. Bradley, C.S. Platta, and B.M. Anderson; University of Wisconsin, Madison, WI . Predictive Factors for Re Volume 84 Number 3S Supplement 2012.currence Following Postoperative Vaginal Cuff Brachytherapy Alone for Stage I Endometrial Cancer .
- Kumari PR, Renuka IV, Apuroopa M, Chaganti PD. A study of expression of estrogen and progesterone receptor, in atrophic, hyperplastic and malignant endometrial lesions, with emphasis on relationship with prognostic parameters. Int J Res Med Sci 2015;3:3318-25.
- Shen F, Gao Y, Ding J, Chen Q. Is the positivity of estrogen receptor or progesterone receptor different between type 1 and type 2 endometrial cancer? Oncotarget. 2017;8: 506-11. doi:10.18632/oncotarget.13471.
- Deborah Smith , ER and PR expression and survival after endometrial cancer. 22 November 2017.
- Caifeng Wang, Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Markers in Endometrial Cancer. 2020;11:1693-701.
- Nayar Musfera Abdul Masjeed1,Immunohistochemical Study of ER, PR, Ki67 and p53 in
Endometrial Hyperplasias and Endometrial Carcinomas. 10.7860/JCDR/2017/28750.10475.
- Yue Wang, M.S.,Comparison of Different Scoring Systems in the Assessment of Estrogen Receptor Status for Predicting Prognosis in Endometrial Cancer . 00:1–8, Lippincott Williams & Wilkins, Baltimore.Copyright © 2018 by the International Society of Gynecological Pathologists.
- Jun Guan ,The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification. J Gynecol Oncol. 2019;30:e13.
- Kerner H, Sabo E, Friedman M, Beck D, Samare O, Lichtig C: An immunohistochemical study of estrogen and progesterone receptors in adenocarcinoma of the endometrium and in the adjacent mucosa. Int J Gynecol Cancer. 1995;5:275-81. 10.1046/j.1525- 1438.1995.05040275.x.
- Markman M: Hormonal therapy of endometrial cancer. Eur J Cancer. 2005;41:673-75. 10.1016/j.ejca.2004.12.008.
- Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW: Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol. 2000;13: 379-88. 10.1038/modpathol.3880062.
- Gul AE, Keser SH, Barisik NO, Kandemir NO, Cakır C, Sensu S, Karadayi N: The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas. Diagn Pathol. 2010;5:13-10.1186/1746- 1596-5-13.
- GEOFFROY CANLORBE Contribution of Immunohistochemical Profile in Assessing Histological Grade of Endometrial Cancer. ANTICANCER RESEARCH 2013;33: 2191-98.
- Caifeng Wang, Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Markers in Endometrial Cancer, J Cancer. 2020;11:1693–701.
- Utaaker E, Iversen OE, Skaarland E: The distribution and prognostic implications of steroid receptors in endometrial carcinomas. Gynecol Oncol 1987;28:89–100.
- Budwit-Novotny DA, McCarty KS, Cox EB, Soper JT, Mutch DG, Creasman WT, Flowers JL, McCarty KS Jr: Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 1986;46:5419–25.
- Carcangiu ML, Chambers JT, Voynick IM, Pirro M, Schwartz PE: Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: clinical and histologic correlations. Am J Clin Pathol 1990;94:247–54.
- Mutch DG, Soper JT, Budwit-Novotny DA, Cox EB, Creasman WT,McCarty KS Jr: Endometrial adenocarcinoma estrogen receptor content: association of clinicopathologic features with immunohistochemical analysis compared with standard biochemical methods. centre study into the reliability of steroid receptor immunocytochemical Am J Obstet Gynecol 1987;157:924–31.
- Kadar N, Malfetano JH, Homesley HD: Steroid receptor concentrations in endometrial carcinoma: Effect on survival in surgically staged patients. Gynecol Oncol 50:281 –286, 1993.
- Chambers JT, MacLusky N, Eisenfield A, Kohorn E, Lawrence R Schwartz PE: Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer. Gynecol Oncol 1988;31:65–81.
- Kauppila A, Kujansuu E, Vihko R: Cytosol estrogen and progestin receptors in endometrial carcinoma in patients treated with surgery,radiotherapy, and progestin: clinical correlates. Cancer 1982;50:2157–62.
- Ramirez PT, Frumovitz M, Bodurka DC, et al. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol. 2004;95:133‒38.
- Soper JT, McCarty KS, Creasman WT, ClarkePearson DL, McCarty KS: Induction of cytoplasmic progesterone receptor in human endometrial carcinoma transplanted into nude mice. Am J Obstet Gyneco. 1984;150: 437- 39. 10.1016/S0002-9378(84)80159-3.
|